Spero Therapeutics, Inc. files DEF 14A for annual meeting.
Ticker: SPRO · Form: DEF 14A · Filed: Apr 16, 2024 · CIK: 1701108
| Field | Detail |
|---|---|
| Company | Spero Therapeutics, Inc. (SPRO) |
| Form Type | DEF 14A |
| Filed Date | Apr 16, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 20 min |
| Key Dollar Amounts | $20,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: DEF 14A, Proxy Statement, Executive Compensation, Corporate Governance, Spero Therapeutics
TL;DR
<b>Spero Therapeutics, Inc. has filed its Definitive Proxy Statement (DEF 14A) detailing corporate governance and executive compensation information.</b>
AI Summary
Spero Therapeutics, Inc. (SPRO) filed a Proxy Statement (DEF 14A) with the SEC on April 16, 2024. Spero Therapeutics, Inc. filed a DEF 14A form on April 16, 2024. The filing covers the period ending May 29, 2024. The company's principal executive offices are located at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139. Spero Therapeutics, Inc. was formerly known as Spero Therapeutics, LLC, with a name change date of March 16, 2017. The Standard Industrial Classification code for the company is Pharmaceutical Preparations [2834].
Why It Matters
For investors and stakeholders tracking Spero Therapeutics, Inc., this filing contains several important signals. This DEF 14A filing is crucial for shareholders to understand executive compensation structures and make informed voting decisions at the upcoming annual meeting. The document provides transparency into the company's financial performance and how it relates to executive pay, which is a key area of focus for investors.
Risk Assessment
Risk Level: low — Spero Therapeutics, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, which typically contains standard disclosures about executive compensation and corporate governance, posing no immediate or unusual risks.
Analyst Insight
Shareholders should review the executive compensation details and any proposed governance changes to inform their voting decisions.
Key Numbers
- 2024-04-16 — Filing Date (DEF 14A filing date)
- 2024-05-29 — Period of Report (Conformed period of report)
- 001-38266 — SEC File Number (SEC file number for Spero Therapeutics, Inc.)
- 24847948 — Film Number (SEC film number)
- 20170316 — Date of Name Change (Date Spero Therapeutics, LLC changed its name)
Key Players & Entities
- Spero Therapeutics, Inc. (company) — Filer
- Spero Therapeutics, LLC (company) — Former company name
- Cambridge, MA (location) — Business address city and state
- 02139 (location) — Business address zip code
- 2834 (industry) — Standard Industrial Classification
FAQ
When did Spero Therapeutics, Inc. file this DEF 14A?
Spero Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 16, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Spero Therapeutics, Inc. (SPRO).
Where can I read the original DEF 14A filing from Spero Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Spero Therapeutics, Inc..
What are the key takeaways from Spero Therapeutics, Inc.'s DEF 14A?
Spero Therapeutics, Inc. filed this DEF 14A on April 16, 2024. Key takeaways: Spero Therapeutics, Inc. filed a DEF 14A form on April 16, 2024.. The filing covers the period ending May 29, 2024.. The company's principal executive offices are located at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139..
Is Spero Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, Spero Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine DEF 14A, which typically contains standard disclosures about executive compensation and corporate governance, posing no immediate or unusual risks.
What should investors do after reading Spero Therapeutics, Inc.'s DEF 14A?
Shareholders should review the executive compensation details and any proposed governance changes to inform their voting decisions. The overall sentiment from this filing is neutral.
How does Spero Therapeutics, Inc. compare to its industry peers?
Spero Therapeutics, Inc. operates in the Pharmaceutical Preparations industry.
Are there regulatory concerns for Spero Therapeutics, Inc.?
The filing is a DEF 14A, a standard SEC form for definitive proxy statements.
Industry Context
Spero Therapeutics, Inc. operates in the Pharmaceutical Preparations industry.
Regulatory Implications
The filing is a DEF 14A, a standard SEC form for definitive proxy statements.
What Investors Should Do
- Review executive compensation details provided in the DEF 14A.
- Understand proposed amendments to corporate governance policies.
- Prepare for upcoming shareholder voting at the annual meeting.
Year-Over-Year Comparison
This is a DEF 14A filing, which is a routine disclosure for annual meetings and does not represent a change from previous filing types.
Filing Stats: 4,884 words · 20 min read · ~16 pages · Grade level 11.5 · Accepted 2024-04-16 16:11:48
Key Financial Figures
- $20,000 — ments, which are not expected to exceed $20,000 in total. What Constitutes a Quorum f
Filing Documents
- d599560ddef14a.htm (DEF 14A) — 828KB
- g599560dsp155.jpg (GRAPHIC) — 1KB
- g599560dsp155a.jpg (GRAPHIC) — 5KB
- g599560dsp155b.jpg (GRAPHIC) — 4KB
- g599560dsp155c.jpg (GRAPHIC) — 2KB
- g599560g02a02.jpg (GRAPHIC) — 22KB
- g599560g27s26.jpg (GRAPHIC) — 101KB
- g599560g82i09.jpg (GRAPHIC) — 73KB
- g599560g90e67.jpg (GRAPHIC) — 64KB
- 0001193125-24-097749.txt ( ) — 2132KB
- spro-20231231.xsd (EX-101.SCH) — 5KB
- spro-20231231_def.xml (EX-101.DEF) — 6KB
- spro-20231231_lab.xml (EX-101.LAB) — 8KB
- spro-20231231_pre.xml (EX-101.PRE) — 5KB
- d599560ddef14a_htm.xml (XML) — 183KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 9 MANAGEMENT AND CORPORATE GOVERNANCE MATTERS 11 EXECUTIVE OFFICER AND DIRECTOR COMPENSATION 22 EQUITY COMPENSATION PLANS AND OTHER BENEFIT PLANS 38 REPORT OF AUDIT COMMITTEE 41 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 42 PROPOSAL 1 : ELECTION OF DIRECTORS 44 PROPOSAL 2 : INDEPENDENT PUBLIC ACCOUNTING FIRM 45 PROPOSAL 3 : ADVISORY VOTE ON APPROVAL OF EXECUTIVE COMPENSATION AS DISCLOSED IN THIS PROXY STATEMENT 47 PROPOSAL 4: AMENDMENT TO 2017 STOCK INCENTIVE PLAN, AS AMENDED 48 CODE OF CONDUCT AND ETHICS 56 OTHER MATTERS 56 STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR 56 APPENDIX A - SPERO THERAPEUTICS, INC. 2017 STOCK INCENTIVE PLAN, AS AMENDED 1 i Table of Contents SPERO THERAPEUTICS, INC. 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts 02139 PROXY STATEMENT FOR SPERO THERAPEUTICS, INC. 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 29, 2024 This proxy statement, along with the accompanying notice of 2024 annual meeting of stockholders, contains information about the 2024 annual meeting of stockholders of Spero Therapeutics, Inc. (the "Annual Meeting"), including any adjournments or postponements of the Annual Meeting. We are holding the Annual Meeting at 9:00 a.m. Eastern Time on May 29, 2024. This year's Annual Meeting will be conducted solely via live audio webcast on the Internet. You will be able to attend the Annual Meeting, vote and submit your questions during the Annual Meeting by visiting www.virtualshareholdermeeting.com/SPRO2024. You will not be able to attend the Annual Meeting in person. In this proxy statement, we refer to Spero Therapeutics, Inc. as "Spero," "the Company," "we" and "us." This proxy statement relates to the solicitation of proxies by our board of directors ("Board of Directors") for use at the Annual Meeting. On or about April 16, 2024, we intend to begin se